Cardio-Immuno-Oncology
Vlad G. Zaha, Wouter C. Meijers, Javid J. Moslehi
Abstract
he burgeoning field of cardio-oncology is continuing to grow in step with major scientific developments in oncology that have improved cancer prognosis and survivorship. Once focused primarily on addressing the effects of conventional chemotherapy, cardio-oncology is now increasingly defining itself in relation to acute and chronic cardiovascular and metabolic risks of targeted oncologic therapies. 1 In a bidirectional interaction, cardio-oncology holds the potential for bridging the application of fundamental molecular advances from hematology and oncology in the cardiovascular field. These concepts are now amalgamating in cardio-immuno-oncology or the cardiovascular sequelae of cancer therapies modulating the immune system.